Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1990 Feb;58(2):373–377. doi: 10.1128/iai.58.2.373-377.1990

Synthesis and characterization of Escherichia coli O18 O-polysaccharide conjugate vaccines.

S J Cryz Jr 1, A S Cross 1, J C Sadoff 1, E Fürer 1
PMCID: PMC258465  PMID: 2105272

Abstract

Nontoxic, serologically reactive O polysaccharide was derived from Escherichia coli O18 lipopolysaccharide by acid hydrolysis, extraction with organic solvents, and gel filtration chromatography. Oxidized O polysaccharide was covalently coupled to either Pseudomonas aeruginosa toxin A or cholera toxin by using adipic acid dihydrazide as a spacer molecule in the presence of carbodiimide. The resulting conjugates were composed of approximately equal amounts of O polysaccharide and protein and were nontoxic and nonpyrogenic. Both conjugates engendered an immunoglobulin G antibody response in rabbits that recognized native O18 lipopolysaccharide. Such antibody was able to promote the uptake and killing of an E. coli O18 strain bearing the K1 capsule by human polymorphonuclear leukocytes. Immunoglobulin G isolated from the sera of rabbits immunized with either conjugate afforded protection against an E. coli O18 challenge when passively transferred to mice.

Full text

PDF
373

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alpern M., Garciacelay Z., Hooper J. Opsonophagocytic activity of intravenous immunoglobulins. Lancet. 1987 Jul 11;2(8550):97–97. doi: 10.1016/s0140-6736(87)92756-5. [DOI] [PubMed] [Google Scholar]
  2. Bryan C. S., Reynolds K. L., Brenner E. R. Analysis of 1,186 episodes of gram-negative bacteremia in non-university hospitals: the effects of antimicrobial therapy. Rev Infect Dis. 1983 Jul-Aug;5(4):629–638. doi: 10.1093/clinids/5.4.629. [DOI] [PubMed] [Google Scholar]
  3. Cross A. S., Gemski P., Sadoff J. C., Orskov F., Orskov I. The importance of the K1 capsule in invasive infections caused by Escherichia coli. J Infect Dis. 1984 Feb;149(2):184–193. doi: 10.1093/infdis/149.2.184. [DOI] [PubMed] [Google Scholar]
  4. Cross A. S., Kim K. S., Wright D. C., Sadoff J. C., Gemski P. Role of lipopolysaccharide and capsule in the serum resistance of bacteremic strains of Escherichia coli. J Infect Dis. 1986 Sep;154(3):497–503. doi: 10.1093/infdis/154.3.497. [DOI] [PubMed] [Google Scholar]
  5. Cross A. S., Zollinger W., Mandrell R., Gemski P., Sadoff J. Evaluation of immunotherapeutic approaches for the potential treatment of infections caused by K1-positive Escherichia coli. J Infect Dis. 1983 Jan;147(1):68–76. doi: 10.1093/infdis/147.1.68. [DOI] [PubMed] [Google Scholar]
  6. Cryz S. J., Jr, Fürer E., Cross A. S., Wegmann A., Germanier R., Sadoff J. C. Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans. J Clin Invest. 1987 Jul;80(1):51–56. doi: 10.1172/JCI113062. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cryz S. J., Jr, Fürer E., Germanier R. Protection against Pseudomonas aeruginosa infection in a murine burn wound sepsis model by passive transfer of antitoxin A, antielastase, and antilipopolysaccharide. Infect Immun. 1983 Mar;39(3):1072–1079. doi: 10.1128/iai.39.3.1072-1079.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Cryz S. J., Jr, Fürer E., Sadoff J. C., Germanier R. A polyvalent Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine. Antibiot Chemother (1971) 1987;39:249–255. doi: 10.1159/000414350. [DOI] [PubMed] [Google Scholar]
  9. Cryz S. J., Jr Prospects for the prevention and control of gram-negative nosocomial infections. Vaccine. 1987 Dec;5(4):261–265. doi: 10.1016/0264-410x(87)90147-2. [DOI] [PubMed] [Google Scholar]
  10. Cryz S. J., Jr, Sadoff J. C., Fürer E., Germanier R. Pseudomonas aeruginosa polysaccharide-tetanus toxoid conjugate vaccine: safety and immunogenicity in humans. J Infect Dis. 1986 Oct;154(4):682–688. doi: 10.1093/infdis/154.4.682. [DOI] [PubMed] [Google Scholar]
  11. Fürer E., Cryz S. J., Jr, Dorner F., Nicolet J., Wanner M., Germanier R. Protection against colibacillosis in neonatal piglets by immunization of dams with procholeragenoid. Infect Immun. 1982 Mar;35(3):887–894. doi: 10.1128/iai.35.3.887-894.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Germanier R., Fürer E., Varallyay S., Inderbitzin T. M. Preparation of a purified antigenic cholera toxoid. Infect Immun. 1976 Jun;13(6):1692–1698. doi: 10.1128/iai.13.6.1692-1698.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Granström M., Wretlind B., Markman B., Cryz S. Enzyme-linked immunosorbent assay to evaluate the immunogenicity of a polyvalent Klebsiella capsular polysaccharide vaccine in humans. J Clin Microbiol. 1988 Nov;26(11):2257–2261. doi: 10.1128/jcm.26.11.2257-2261.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Horan T. C., White J. W., Jarvis W. R., Emori T. G., Culver D. H., Munn V. P., Thornsberry C., Olson D. R., Hughes J. M. Nosocomial infection surveillance, 1984. MMWR CDC Surveill Summ. 1986;35(1):17SS–29SS. [PubMed] [Google Scholar]
  15. Kaijser B., Ahlstedt S. Protective capacity of antibodies against Escherichia coli and K antigens. Infect Immun. 1977 Aug;17(2):286–289. doi: 10.1128/iai.17.2.286-289.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kim K. S., Kang J. H., Cross A. S., Kaufman B., Zollinger W., Sadoff J. Functional activities of monoclonal antibodies to the O side chain of Escherichia coli lipopolysaccharides in vitro and in vivo. J Infect Dis. 1988 Jan;157(1):47–53. doi: 10.1093/infdis/157.1.47. [DOI] [PubMed] [Google Scholar]
  17. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  18. McCabe W. R., Kaijser B., Olling S., Uwaydah M., Hanson L. A. Escherichia coli in bacteremia: K and O antigens and serum sensitivity of strains from adults and neonates. J Infect Dis. 1978 Jul;138(1):33–41. doi: 10.1093/infdis/138.1.33. [DOI] [PubMed] [Google Scholar]
  19. McCabe W. R., Kreger B. E., Johns M. Type-specific and cross-reactive antibodies in gram-negative bacteremia. N Engl J Med. 1972 Aug 10;287(6):261–267. doi: 10.1056/NEJM197208102870601. [DOI] [PubMed] [Google Scholar]
  20. McGowan J. E., Jr, Barnes M. W., Finland M. Bacteremia at Boston City Hospital: Occurrence and mortality during 12 selected years (1935-1972), with special reference to hospital-acquired cases. J Infect Dis. 1975 Sep;132(3):316–335. doi: 10.1093/infdis/132.3.316. [DOI] [PubMed] [Google Scholar]
  21. Orskov I., Orskov F. Escherichia coli in extra-intestinal infections. J Hyg (Lond) 1985 Dec;95(3):551–575. doi: 10.1017/s0022172400060678. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. PARK J. T., JOHNSON M. J. A submicrodetermination of glucose. J Biol Chem. 1949 Nov;181(1):149–151. [PubMed] [Google Scholar]
  23. Pluschke G., Achtman M. Antibodies to O-antigen of lipopolysaccharide are protective against neonatal infection with Escherichia coli K1. Infect Immun. 1985 Aug;49(2):365–370. doi: 10.1128/iai.49.2.365-370.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Pluschke G., Mayden J., Achtman M., Levine R. P. Role of the capsule and the O antigen in resistance of O18:K1 Escherichia coli to complement-mediated killing. Infect Immun. 1983 Dec;42(3):907–913. doi: 10.1128/iai.42.3.907-913.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Que J. U., Cryz S. J., Jr, Ballou R., Fürer E., Gross M., Young J., Wasserman G. F., Loomis L. A., Sadoff J. C. Effect of carrier selection on immunogenicity of protein conjugate vaccines against Plasmodium falciparum circumsporozoites. Infect Immun. 1988 Oct;56(10):2645–2649. doi: 10.1128/iai.56.10.2645-2649.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Schneerson R., Robbins J. B., Chu C., Sutton A., Vann W., Vickers J. C., London W. T., Curfman B., Hardegree M. C., Shiloach J. Serum antibody responses of juvenile and infant rhesus monkeys injected with Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-protein conjugates. Infect Immun. 1984 Sep;45(3):582–591. doi: 10.1128/iai.45.3.582-591.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Schneerson R., Robbins J. B., Parke J. C., Jr, Bell C., Schlesselman J. J., Sutton A., Wang Z., Schiffman G., Karpas A., Shiloach J. Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates. Infect Immun. 1986 May;52(2):519–528. doi: 10.1128/iai.52.2.519-528.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Schutze M. P., Leclerc C., Jolivet M., Audibert F., Chedid L. Carrier-induced epitopic suppression, a major issue for future synthetic vaccines. J Immunol. 1985 Oct;135(4):2319–2322. [PubMed] [Google Scholar]
  29. Setia U., Serventi I., Lorenz P. Bacteremia in a long-term care facility. Spectrum and mortality. Arch Intern Med. 1984 Aug;144(8):1633–1635. [PubMed] [Google Scholar]
  30. Stamm W. E., Martin S. M., Bennett J. V. Epidemiology of nosocomial infection due to Gram-negative bacilli: aspects relevant to development and use of vaccines. J Infect Dis. 1977 Aug;136 (Suppl):S151–S160. doi: 10.1093/infdis/136.supplement.s151. [DOI] [PubMed] [Google Scholar]
  31. Todeschini G., Vinante F., Benini F., Perini A., Pasini F., Cetto G. Gram-negative septicemia in patients with hematologic malignancies. Eur J Cancer Clin Oncol. 1984 Mar;20(3):327–331. doi: 10.1016/0277-5379(84)90077-4. [DOI] [PubMed] [Google Scholar]
  32. Weinstein M. P., Reller L. B., Murphy J. R., Lichtenstein K. A. The clinical significance of positive blood cultures: a comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. I. Laboratory and epidemiologic observations. Rev Infect Dis. 1983 Jan-Feb;5(1):35–53. doi: 10.1093/clinids/5.1.35. [DOI] [PubMed] [Google Scholar]
  33. van Furth R., Leijh P. C., Klein F. Correlation between opsonic activity for various microorganisms and composition of gammaglobulin preparations for intravenous use. J Infect Dis. 1984 Apr;149(4):511–517. doi: 10.1093/infdis/149.4.511. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES